An De Weer
Ghent University Hospital
6 Papers
11 Citations
An De Weer is an academic researcher from Ghent University Hospital. The author has contributed to research in topics: Myeloid leukemia & Myeloid. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22
An De Weer,Franki Speleman,Barbara Cauwelier,Nadine Van Roy,Nurten Yigit,Bruno Verhasselt,Barbara De Moerloose,Yves Benoit,Lucien Noens,Dominik Selleslag,Eric Lippert,Stéphanie Struski,Christian Bastard,Anne De Paepe,Peter Vandenberghe,Anne Hagemeijer,Nicole Dastugue,Bruce Poppe +17 more
TL;DR: It is shown for the first time that the t(3;17) is indeed a recurrent chromosomal aberration in myeloid malignancies and overexpression of the EVI1 gene appears to be the major contributor to leukemogenesis in patients with a t( 3;17).
34
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
François Duhoux,Geneviève Ameye,Virginie Lambot,Christian Herens,Frédéric Lambert,Sophie Raynaud,Iwona Wlodarska,Lucienne Michaux,Catherine Roche-Lestienne,Elise Labis,Sylvie Taviaux,Elise Chapiro,Florence Nguyen Khac,Stéphanie Struski,Sophie Dobbelstein,Nicole Dastugue,Eric Lippert,Frank Speleman,Nadine Van Roy,An De Weer,Katrina Rack,Pascaline Talmant,Steven Richebourg,Francine Mugneret,Isabelle Tigaud,Marie-Joelle Mozziconacci,Sophy Laibe,Nathalie Nadal,Christine Terré,Jeanne-Marie Libouton,Anabelle Decottignies,Miikka Vikkula,Hélène Poirel +32 more
TL;DR: Fluorescence in situ hybridization was performed to characterize 81 cases of myeloid and lymphoid malignancies with cytogenetic 1p36 alterations not affecting the PRDM16 locus, and found novel partner loci on 1p 36 for the known multi-partner genes HMGA2 and RUNX1.
22
EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22)
An De Weer,Bruce Poppe,Barbara Cauwelier,Andre Carlier,Jan Dierick,Bruno Verhasselt,Jan Philippé,Nadine Van Roy,Frank Speleman +8 more
TL;DR: Molecular analysis of variants of t(9;22) can specifically target a second oncogene most likely contributing to the more aggressive phenotype of the disease to open the way for combined molecular therapies in order to tackle the secondary oncogenic effect which is unresponsive to imatinib treatment.
11
EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells
An De Weer,Joni Van der Meulen,Pieter Rondou,Tom Taghon,Torsten A. Konrad,Katleen De Preter,Pieter Mestdagh,Tom Van Maerken,Nadine Van Roy,Marta Jeison,Isaac Yaniv,Barbara Cauwelier,Lucien Noens,Hélène-Antoine Poirel,Peter Vandenberghe,Frédéric Lambert,Anne De Paepe,Maria Garcia Sanchez,María D. Odero,Bruno Verhasselt,Jan Philippé,J Vandesompele,Rotraud Wieser,Nicole Dastugue,Pieter Van Vlierberghe,Bruce Poppe,Frank Speleman +26 more
TL;DR: MIR449A is revealed as a crucial direct target of the MECOM locus protein EVI1 involved in the pathogenesis of MECom‐rearranged leukaemias and unravels NOTCH1 and BCL2 as important novel targets of MIR449 a.
Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs.
Pieter Van Vlierberghe,An De Weer,Pieter Mestdagh,Tom Feys,Katleen De Preter,Pascale De Paepe,Kathleen Lambein,Jo Vandesompele,Nadine Van Roy,Bruno Verhasselt,Bruce Poppe,Frank Speleman +11 more
TL;DR: The data suggest that miRNAs are implicated in the pathogenesis of Hodgkin lymphoma and prompt further investigations concerning their role in cHL.